Nasopharyngeal Carcinoma in combination with Coherus discovered Toripalimab, novel therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Toripalimab, is an anti-PD-1 monoclonal antibodyhaving the ability to block PD-1interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Blocking of PD-1 interactions with PD-L1 and PD-L2will help toboost the immune systemto attack and kill tumor cells.
Toripalimabin combination with chemotherapyachievedsignificant and clinical improvements in progression free survival (“PFS”) when compared with chemotherapy alone. In addition, toripalimab in combination with chemotherapyprovides as the first-line treatment of nasopharyngeal carcinoma (NPC).
Toripalimab, is the novel PD-1 blocking antibodydeveloped for nasopharyngeal carcinoma. Moreover, nasopharyngeal carcinoma is the aggressive cancer with no immuno-oncology treatment options approved in the United States.
Ongoing clinical trials of are being conducted to evaluate the safety and efficacy of toripalimab for tumortypes including cancers such as stomach, breast, kidney, nasopharynx, lung, esophagus and skin.
Toripalimab received Breakthrough Therapy Designation (BTD) by the United States Food and Drug Administration (“FDA”) for first line treatment of Nasopharyngeal Carcinoma.
